TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35500846
Drug: Micro-infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-infusion pump at 2 ml/h without accompanying fluid (Observation group)
Study: 35500846
Drug: Micro-infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-infusion pump at 2 ml/h with normal saline (Control group)
Study: 34055118
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health status measured by OHI-S
Study: 32053557
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (6.5 ± 1.8 ml/kg predicted body weight)
Study: 32053557
Drug: Intermediate tidal
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate tidal volume ventilation (9.5 ± 1.6 ml/kg predicted body weight)
Study: 35491787
Drug: PBM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM therapy (real light therapy)
Study: 35786297
Drug: Chiropractic spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic spinal manipulative therapy and exercise
Study: 36309744
Drug: Electronic pillbox
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic pillbox intervention with pre-filled weekly blister pack medication trays, alarms, detection of pill removal, alerts to patients or caregivers, adherence reports, and pharmacist outreach for missed doses.
Study: 34474731
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg daily for 3 days)
Study: 33734782
Drug: Cognitive-behavioral substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral substance use treatment (standard)
Study: 33734782
Drug: Cognitive-behavioral substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral substance use treatment (culturally accommodated)
Study: 34023938
Drug: Wild blueberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild blueberry (WBB) drink intervention (766 mg total polyphenols; 253 mg anthocyanins; equivalent to 240 g fresh blueberries per day)
Study: 32739320
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose to the posterior prostate and surrounding regions in RADAR and RT01 patients
Study: 32739320
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose to the seminal vesicle region in RADAR intermediate-risk patients
Study: 32641470
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 220 mg
Study: 36088627
Drug: Intralesional measles,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional measles, mumps, and rubella (MMR) vaccine
Study: 34097368
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg on days 1, 15, 168, and 182)
Study: 32096120
Drug: High cumulative
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cumulative propofol dose (1316 mg/kg)
Study: 34340096
Drug: Shangliao point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shangliao point injection combined with epidural analgesia
Study: 34340096
Drug: Shangliao point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shangliao point injection
Study: 34340096
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia and saline injection
Study: 32593779
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (150 mg/day)
Study: 32926259
Drug: Transinguinal preperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transinguinal preperitoneal repair with modified Kugel patch (MK)
Study: 32641101
Drug: Bortezomib (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (up to 3 cycles, each 21 days with 4 subcutaneous applications)
Study: 32641101
Drug: Placebo (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (up to 3 cycles, each 21 days with 4 subcutaneous applications)
Study: 36222880
Drug: 10-mg dose
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mg dose of amiloride
Study: 34922807
Drug: Mobilization Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization Group (MG) - five days of standard gait training and early ambulation
Study: 35605176
Drug: Venetoclax-rituximab (VenR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax-rituximab (VenR) with undetectable minimal residual disease (uMRD) at end of treatment (EOT)
Study: 36241511
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid administered before surgical incision (pre-induction groups)
Study: 36241511
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid administered just before tourniquet release (pre-release groups)
Study: 36241511
Drug: Single-dose groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose groups (tranexamic acid administered once)
Study: 36241511
Drug: Double-dose groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose groups (tranexamic acid administered twice)
Study: 36241511
Drug: Double-dose groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose groups
Study: 37682887
Drug: Antibiotic paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic paste (CTZ)
Study: 33991032
Drug: Carboxytherapy (intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxytherapy (intradermal injection of 5 cc carbon-dioxide gas once weekly for 6 weeks)
Study: 33991032
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) therapy (intradermal injection of PRP every 2 weeks for three times)
Study: 32199156
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose of 0.65 g/kg
Study: 32529495
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) treatment
Study: 32466879
Drug: Mavacamten (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten (200 ng/ml)
Study: 32466879
Drug: Mavacamten (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten (500 ng/ml)
Study: 32920767
Drug: 40 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 Gy equivalent dose
Study: 32920767
Drug: 50 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 Gy equivalent dose
Study: 32629757
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (6000 IU daily for eight weeks)
Study: 35093047
Drug: Guided internet-
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet- and mobile-based cognitive behavioral therapy (iCBT) youthCOACHCD (IG, n=15)
Study: 35093047
Drug: Guided internet-
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet- and mobile-based cognitive behavioral therapy (iCBT) youthCOACHCD (IG)
Study: 35597965
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation program combining multimodal exercises with psychologist-led cognitive-behavioral therapy sessions
Study: 34812096
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (MFR and NAFL)
Study: 33607008
Drug: lumacaftor–ivacaftor therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumacaftor–ivacaftor therapy
Study: 35436611
Drug: SpikoGen® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SpikoGen® vaccine (25 μg, two doses, 3 weeks apart)
Study: 32978182
Drug: Mirror Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror Therapy (MT) combined with task-oriented training
Study: 36252934
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lutein + 2 mg zeaxanthin
Study: 32363968
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine infusion of 0.5 ml of platelet-rich plasma (PRP) 48 hours before embryo transfer
Study: 32938470
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) starting from 5 mg per week for the first 2 weeks, increasing to 10 mg per week for the second 2 weeks, and 15 mg per week for the remaining period if tolerated
Study: 34614204
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg ramosetron with IV-PCA
Study: 34614204
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexamethasone before induction of anesthesia with IV-PCA
Study: 32925205
Drug: Tumor-treating fields
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor-treating fields therapy
Study: 35047630
Drug: Ulinastatin combined
Normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin combined with Xingnaojing injection
Study: 36409064
Drug: CTN-1 V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CTN-1 V human rabies vaccine (Vero cells) administered via the Essen Regimen (single dose on days 0, 3, 7, 14, and 28)
Study: 36409064
Drug: CTN-1 V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CTN-1 V human rabies vaccine (Vero cells)
Study: 33586072
Drug: Conventional chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemoradiation therapy after induction chemotherapy
Study: 33586072
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of local ablation and immunotherapy
Study: 36105647
Drug: Natural control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural control (CK) treatment
Study: 35363600
Drug: Baseline FVC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline FVC bronchodilator responsiveness
Study: 35363600
Drug: Interactions between
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactions between lung function reduction and treatment assignment
Study: 35363600
Drug: Baseline bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline bronchodilator responsiveness measures
Study: 33529588
Drug: 0.25% topical
Normalized name: Remyda, 0.25% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% topical ocular reproxalap
Study: 32408117
Drug: Saffron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron supplementation (100 mg/day)
Study: 32876858
Drug: Qingfei Yihuo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingfei Yihuo Capsules (QYCs)
Study: 33100187
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioral Therapy (CBT) for 12 weeks
Study: 35972345
Drug: CIRAS model
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIRAS model (developed using variables: ascites discomfort score, plasma sodium levels, and a composite of ascites accumulation and diuretic treatment)
Study: 35963986
Drug: Bosutinib 400
Normalized name: bosutinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 400 mg once daily
Study: 34544463
Drug: Solnatide (AP301),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solnatide (AP301), administered twice daily for 7 days
Study: 34544463
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered twice daily for 7 days
Study: 35189571
Drug: Tongue isometric
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue isometric pressure exercises using the Iowa Oral Performance Instrument with an increasing scheme of 5% load weekly and traditional tongue therapy for 8 weeks
Study: 34255938
Drug: Acarbose/Metformin Fixed-Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose/Metformin Fixed-Dose Combination (50 mg/500 mg)
Study: 34255938
Drug: Loose combination
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose combination of individual components (Acarbose and Metformin)
Study: 34644419
Drug: Lidocaine 10%
Normalized name: LIDOCAINE 10% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 10% spray (50 mg)
Study: 33836807
Drug: Yijinjing exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yijinjing exercise intervention combined with routine rehabilitation therapy (40 min/session, 3 sessions/week for 12 weeks)
Study: 33836807
Drug: Routine rehabilitation
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine rehabilitation therapies (occupational therapy, physical therapy, acupuncture therapy, health education) 5 times a week for 3 months
Study: 35552197
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (2x10^9 cfu/day for 30 days)
Study: 32027620
Drug: Multiple courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple courses of NK cell infusion
Study: 32027620
Drug: Single course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single course of NK cell infusion
Study: 35794080
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of afatinib dimaleate (40 mg)
Study: 35794080
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of afatinib dimaleate (40 mg)
Study: 33515500
Drug: Maintenance intravenous
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance intravenous gemcitabine (1250 mg/m2 on days 1 and 8, in cycles of 21 days) plus supportive care
Study: 33420185
Drug: HYAJOINT Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYAJOINT Plus (3 ml, 20 mg/ml) followed by PRP (3 ml)
Study: 33420185
Drug: PRP (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP (3 ml)
Study: 32553394
Drug: Continuing unilateral
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing unilateral ECT with antidepressants
Study: 35719197
Drug: Cooling gel
Normalized name: Cooling Gel
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling gel pad application for 20 minutes duration once a day (n = 20)
Study: 35719197
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac gel application 4 times a day (n = 20)
Study: 35997582
Drug: 9-valent HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent HPV vaccine (9vHPV)
Study: 34450552
Drug: idd epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC)
Study: 34450552
Drug: Leucocyte nadir-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by tailored and dose-dense docetaxel (dtD) (dtEC-dtD)
Study: 35760910
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg daily
Study: 34895483
Drug: Adrecizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrecizumab (8 mg/kg bodyweight)
Study: 32740502
Drug: 3.0 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 µg/kg IND
Study: 32740502
Drug: 3.5 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 µg/kg IND
Study: 33742520
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K (menadiol diphosphate 5 mg, thrice weekly)
Study: 32421762
Drug: Ivermectin mass
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin mass drug administration (MDA) for scabies
Study: 33859155
Drug: Immediate-Release Tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-Release Tacrolimus (IR-Tac)
Study: 32000711
Drug: Icotinib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib (125 mg, thrice a day)
Study: 32000711
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg, once a day)
Study: 35210069
Drug: Specialized yoga
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized yoga training program in addition to current guideline‐based therapy
Study: 35210069
Drug: Current guideline‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current guideline‐based therapy alone
Study: 32781104
Drug: Pembrolizumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab with radiation therapy (pembroRT)
Study: 34171789
Drug: BGF 320/18/9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF 320/18/9.6 μg
Study: 34171789
Drug: BGF 160/18/9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF 160/18/9.6 μg
Study: 34171789
Drug: GFF 18/9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF 18/9.6 μg
Study: 34171789
Drug: BFF 320/9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFF 320/9.6 μg
Study: 33985595
Drug: Multi-donor FMT
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-donor FMT (capsules containing the fecal microbiota of four sex-matched lean donors)
Study: 33985595
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline capsules)
Study: 33507721
Drug: hCG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG plus GnRH agonist (group B)
Study: 32851885
Drug: OS nomogram
Approvals — FDA: no, EMA: no, PMDA: no
Description: OS nomogram incorporating age, race, histologic grade, AJCC stage, metastasis, surgery, chemotherapy, and tumor size.
Study: 33214244
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg emixustat
Study: 33214244
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg emixustat
Study: 33214244
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg emixustat
Study: 32480307
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin (PRM) 2 mg for 4 weeks
Study: 32926814
Drug: Rifabutin-based triple
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin-based triple therapy (RHB-105)
Study: 32926814
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + omeprazole
Study: 36244398
Drug: Bemarituzumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemarituzumab (15 mg/kg bodyweight) plus mFOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus followed by 2400 mg/m2 over 46 hours)
Study: 36244398
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus mFOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus followed by 2400 mg/m2 over 46 hours)
Study: 35958677
Drug: Pharmacotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapeutic treatment (group P)
Study: 32578279
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (SC-t) 600mg every 3 weeks for 4 cycles
Study: 32578279
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab (IV-t)
Study: 32578279
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab with single injection device (SID)
Study: 35881908
Drug: ACEI/ARB continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ARB continued in patients with eGFR < 45 mL/min
Study: 35881908
Drug: Without ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without ACEI/ARB in patients with eGFR < 45 mL/min
Study: 35881908
Drug: ACEI/ARB continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ARB continued in patients with eGFR ≥ 45 mL/min
Study: 35881908
Drug: Without ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without ACEI/ARB in patients with eGFR ≥ 45 mL/min
Study: 35105604
Drug: Structured prehabilitation
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured prehabilitation exercise intervention during neoadjuvant chemotherapy
Study: 35748757
Drug: External concurrent
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External concurrent occipital and trigeminal neurostimulation
Study: 33618977
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable MM lens 1
Study: 33618977
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable MM lens 2
Study: 32867053
Drug: LL‐37 neutralizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: LL‐37 neutralizing antibody
Study: 35345925
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (Zn tablets 20 mg/day)
Study: 32017677
Drug: Immediate vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate vaccination with rVSVΔ-ZEBOV-GP Ebola vaccine